The Oxford-based clinical artificial intelligence (AI) company Sensyne Health plc, has announced that following its new non-exclusive Strategic Research Agreement (SRA) with Somerset NHS Foundation Trust, also revealed today, that it has has achieved a major objective set when it floated on the London Stock Exchange in August 2018 of growing its anonymised patient database to five million patients.
The agreement will enable the ethical application of clinical AI research to improve patient care and accelerate research into new medicines. The Somerset dataset covers 1.1 million unique patient records from a patient population of approximately 600,000 people.
The new SRA now brings the combined total of anonymised patient data available for analysis by Sensyne to 5.6 million patients. The data enables the ethical application of clinical artificial intelligence research on anonymised patient data to improve patient care and accelerate research into new medicines.
With access to anonymised data on more than five million patients, Sensyne is able to cover a broader range of research across different clinical areas, deliver data insights to speed up the development of novel approaches to new medicines, and develop AI-powered clinical decision support tools to improve patient care.
The unique nature of Sensyne’s business model, where NHS Trusts receive an equity stake in the company, a royalty on revenues that are generated from research undertaken under the SRAs and an investment of up to £250,000 per year over the five-year term, means the NHS has benefitted from Sensyne’s partnership approach in a variety of ways, with long-term benefits potentially to come.
Since August 2018, Sensyne Health said that the NHS has already received a total financial return of £19,460,000 through its relationship with Sensyne, comprising: £18,300,000 via equity ownership in Sensyne of 11.7 per cent, £160,000 in shared revenues and £1,000,000 in IT and technology infrastructure investment
Research conducted by Sensyne using SRA data includes: Stroke prediction, Heart failure treatment, the impact of COVID-19 on lungs and also developing algorithms to predict the risk of intensive care unit admission, invasive mechanical ventilation and death in patients with COVID-19 infection.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: “Reaching this five million patient milestone with our NHS Trust partners is a great achievement and means that together we have created a world-class medical research capability here in the UK. Over the past two years we have demonstrated how Sensyne’s clinical AI can be used to deliver better patient care and to accelerate medical research. We have also shown how our unique partnership model not only delivers clinical benefits but also provides a significant financial return back into the NHS.
“We are experiencing enthusiasm from other NHS Trusts across the UK interested in the Sensyne model and see the potential to grow our anonymised patient database beyond five million. We are also seeing interest in Sensyne’s model beyond the UK, and especially in the US, as other healthcare systems begin to think about how to use their own patient data for medical research in a transparent and fair way.”
Last week the company announced that it had appointed Derek Baird to its senior management team as President, North America to drive the commercial development of the company’s North American operations, building Sensyne’s presence in the US and recruiting a US-based team.